In addition to the receptor used to locate tumor cells, this treatment adds an element that further enhances the immune ...

Among 21 patients, 81% responded at 3 months after infusion of the enhanced CAR T-cell product -- huCART19-IL18, which ...

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. A total of 21 patients received huCART19-IL18.

The safety profile of huCART19-IL18 was similar to that of other CAR-T products. A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a ...